Protocol Ledger

NCT06439225 · Phase III · RECRUITING

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Interventional Phase III clinical trial protocol NCT06439225 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-30 Enrollment: 236 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06439225
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)236 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06439225
Protocol FieldVerified Registry Value
NCT IdentifierNCT06439225
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment236 participants (ESTIMATED)
Registered Start Date2024-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06439225
Hospital Research SiteLocationSite Profile
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->
Cross Cancer InstituteEdmonton, CanadaOpen Hospital Dossier ->
University Health NetworkToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI